VRTX — Vertex Pharmaceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual cashflow statement for Vertex Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	1,177	2,712	2,342	3,322	3,620
Depreciation
Deferred Taxes
Non-Cash Items	184	209	436	595	539
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-66.1	-54.5	-105	341	-266
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	1,569	3,254	2,644	4,130	3,537
Capital Expenditures	-75.5	-260	-235	-205	-258
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-1,160	359	-106	-116	-2,883
Acquisition of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-1,235	99.4	-341	-321	-3,142
Financing Cash Flow Items	4.68	-202	-130	-169	-226
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	127	-505	-1,478	-67.7	-562
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	462	2,868	811	3,712	-140